Immunogenicity of a bivalent recombinant adenovirus expressing VP1 proteins of bovine norovirus and bovine nebovirus in mice and calves Authors: Taoyun Chen, Jun Chu, Xin Song, Qisheng Yu, Gunan Deng, Jiangyong Zeng, Changqing Yu, Bin Zhang Published: 2025 ABSTRACT AbstractBovine norovirus (BNoV) and bovine nebovirus (BNeV) are emerging pathogens responsible for severe diarrhea in calves worldwide. In this study, we constructed a bivalent recombinant adenovirus vector vaccine, designated rAd5-BNoV + BNeV_VP1 encoding the genes for BNoV-VP1 and BNeV-VP1 based on replication-deficient human adenovirus type 5 (rAd5), and evaluated its immunogenicity in mice and calves. Serum antibody responses were assessed by enzyme-linked immunosorbent assay (ELISA) and serum blocking titer 50 (BT50). Results demonstrated that mice immunized with rAd5-BNoV + BNeV_VP1 produced significant VP1-specific IgG titers as early as two weeks post-vaccination. BNoV-VP1-specific IgG antibody titers peaked at 1:105 in both intramuscular (I.M.) and oral groups (n = 6), while BNeV-VP1-specific IgG titers peaked at 1:105 in the I.M. groups (n = 6) and 1:104 in the oral groups (n = 6). The BT50 values peaked at 640 in the I.M. groups and 576 in the oral groups (n = 6). Furthermore, the percentages of IL-4-producing cells and CD3+CD8+ T cells in splenocytes were significantly elevated in mice immunized via the I.M. route. The vaccine also elicited a robust humoral immune response in calves. Following a booster I.M. injection with rAd5-BNoV + BNeV_VP1, serum BNoV-VP1-specific and BNeV-VP1-specific IgG antibody titers were significantly higher (P ≤ 0.001) compared to controls. The BT50 in immunized calves reached 1:80 at 21 and 35 days post-immunization. These results collectively indicate that rAd5-BNoV + BNeV_VP1 effectively induces immunity against BNoV and BNeV infection.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12866-025-04542-y.Keywords: Bovine norovirus, Bovine nebovirus, Replication-deficient human type 5 adenovirus vector, VP1 protein, Immune effects Introduction Bovine norovirus (BNoV) and bovine nebovirus (BNeV), members of the Caliciviridae family, are emerging pathogens associated with calf diarrhea [1, 2]. Infections in newborn calves can lead to vomiting, diarrhea, dehydration, intestinal injury, and even death [3–5]. In 2018, we reported the detection of BNoV and BNeV in fecal samples from yaks and dairy cows in China [6, 7]. Since then, these viruses have been identified in other regions, garnering increased attention to the risks they pose. Currently, no commercial vaccines are available to prevent diseases caused by BNoV and BNeV. BNoV and BNeV are non-enveloped, single-stranded, positive-sense RNA viruses with genome lengths ranging from 7.3 kb to 7.5 kb [8–10]. The VP1 protein is the major structural protein of caliciviruses and plays critical roles in receptor binding, host specificity, antigenicity, and immunogenicity [11, 12]. Based on complete VP1 gene sequences, BNoV is classified into genotypes GIII.1 and GIII.2 [13], with GIII.2 being the predominant genotype in China [14]. BNeV is classified into genogroups G1 and G2, with G1 further divided into four lineages; G1.1 is the predominant genotype in China [15]. The VP1 proteins from GIII.2 (BNoV) and G1.1 (BNeV) thus represent potential target antigens for vaccine development. The lack of robust in vitro isolation and culture systems for these viruses has shifted focus towards protective antigens for the development of genetically engineered subunit vaccines. Replication-deficient human adenovirus type 5 (rAd5) vectored vaccines, which encode target antigen genes, have gained prominence due to their proven capacity to induce mucosal, humoral, and cellular immune responses [16–20]. For instance, an oral tablet formulation of a recombinant adenovirus vector vaccine based on the VP1 gene of human norovirus (HuNoV) demonstrated significant immunogenicity in phase I clinical trials by stimulating broad and durable mucosal immunity [21]. In this study, we constructed a bivalent recombinant adenovirus vector vaccine candidate, rAd5-BNoV + BNeV_VP1, using an rAd5 backbone and a P2A peptide linker to enable simultaneous expression of BNoV-VP1 and BNeV-VP1 proteins. We subsequently evaluated its specific immunogenicity in BALB/c mice and Holstein calves, assessing its ability to induce antigen-specific humoral and cellular immune responses. Materials and methods Plasmids, cells, and animals HEK-293 cells and AdMax adenovirus system (pDC316 and pBHGlox(delta)E1,3Cre) were obtained from Microbix Biosystems Inc (Canada). HEK-293 cells were cultured at 37℃ under 5% CO2 in Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen, USA) supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen, Australia) and 1% antibiotics (10,000 units/mL of penicillin and 10,000 µg/mL of streptomycin) (Gibco, USA). For this experiment, we sourced female BALB/c mice (specific pathogen-free [SPF], 6–8 weeks) from Chengdu Dossy Experimental Animals Company (Chengdu, China). Commercially raised Holstein male calves (aged 3 months) were sourced from Sichuan Xuebao Dairy Group Company (Chengdu, China). All mice and calves were confirmed to be serologically susceptible to BNoV and BNeV. The animal experiments were conducted according to the guidelines set by the Sichuan Laboratory Animal Welfare and Ethics Committee of the Sichuan Administration Committee of Laboratory Animals. They were approved by the Research Ethics Committee of Southwest Minzu University (reference number SMU-202401073). This study was conducted in compliance with the ARRIVE guidelines to ensure transparent and complete reporting of research involving animals. Construction of recombinant adenovirus expressing VP1 proteins of BNoV and BNeV To select the VP1 target genes of BNoV and BNeV, we first analyzed the amino acid homology of BNoV-VP1 or BNeV-VP1 from NCBI. BNoV-VP1 based on the Bo/MILQ-1/17/CH strain (MK159173.2)which has approximately 98.8%–100% amino acid homology with BNoV-VP1 collected in China and BNeV-VP1 based on the Bo/LN-13/18/CH strain (MH718898.1) which has approximately 93.6%–100% amino acid homology with BNeV-VP1 collected in China were selected as the target genes. Subsequently, BNoV-VP1 and BNeV-VP1 were codon-optimized for increased expression in mammalian cells and synthesized by Songon Biotech (Shanghai, China). The pDC316-BNoV + BNeV_VP1 was generated by subcloning the codon-optimized BNoV_VP1-P2A-BNeV_VP1 gene into the pDC316 shuttle plasmid at the EcoRI/SalI restriction sites. This shuttle plasmid was then co-transfected with the backbone plasmid (pHBGlox(delta)E1,3Cre) into HEK-293 cells using the jetPRIME transfection reagent (POLYPLUS, France) following the manufacturer’s protocol. Once the transfected cells reached confluence and adenovirus-related cytopathic effects were observed, they were collected and subjected to three-thaw cycles to lyse the cells and release the recombinant adenovirus rAd5-BNoV + BNeV_VP1. RT-PCR of rAd5-BNoV + BNeV_VP1 RT-PCR was utilized to analyze the expressions of BNoV-VP1 and BNeV-VP1 genes. The recombinant adenovirus rAd5-BNoV + BNeV_VP1 was inoculated into HEK-293 cells, and after reverse transcription, the VP1 genes of BNoV and BNeV were amplified using universal primers specific to the pDC316 vector (The universal primers for the pDC316 vector were pDC316F: 5’-ACGTGGGTATAAGAGGCG-3’ and pDC316R: 5’-CGATGCTAGACGATCCAG-3‘ [22]). Indirect immunofluorescence assay of rAd5-BNoV + BNeV_VP1 An indirect immunofluorescence assay (IFA) was conducted to measure the expression of BNoV-VP1 and BNeV-VP1 proteins. HEK-293 cells were infected with rAd5-BNoV + BNeV_VP1 at a multiplicity of infection of 0.1 in six-well plates and incubated for 36 h. Polyclonal mouse anti-BNoV-VP1 antibody and anti-BNeV-VP1 antibody, which were prepared by immunizing BALB/c mice with the recombinant BNoV-VP1 protein or recombinant BNeV-VP1 protein expressed in Escherichia coli in our laboratory, respectively. were used as primary antibodies. A fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG antibody (Abcam, UK, 1:100 dilution) was used as the secondary antibody. The presence of the target proteins was confirmed by observing green fluorescence under an inverted fluorescence microscope. Western blotting of rAd5-BNoV + BNeV_VP1 Western blotting was performed to measure the expression of BNoV-VP1 and BNeV-VP1 proteins. HEK-293 cells were infected with rAd5-BNoV + BNeV_VP1 at a multiplicity of infection of 0.1 in six-well plates. At 48 h post-infection, the cells were harvested and lysed using a radioimmunoprecipitation assay buffer (Thermo Scientific, USA). The cell lysate was centrifuged, and the supernatant was boiled with a loading buffer (Thermo Scientific, USA). Proteins were separated on tris-glycine SDS-PAGE gels and transferred to a nitrocellulose membrane. After blocking with 5% nonfat milk in PBS-T for one hour at room temperature, primary antibodies—polyclonal mouse anti-BNeV-VP1 antibody (1:1,000 dilution) and anti-BNoV-VP1 antibody (1:1,000 dilution)—were applied. Horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (Bioss, China, 1:5000 dilution) was added to the membrane as a secondary antibody. In addition, an HRP-conjugated anti-GAPDH antibody (Bioss, China, 1:10,000 dilution) was used to detect GAPDH as an internal control on the same membrane. Protein bands were visualized using a chemiluminescence imaging system (BIO-RAD, USA). Chromatographic purification of recombinant adenovirus The rAd5-BNoV + BNeV_VP1 was purified using Diamond layer 700 BA, which leverages anionic and nonpolar interactions and size exclusion, and diamond Q Mustang, which utilizes electrostatic interactions. The process included initial purification (centrifugation at 10,000 rpm for 10 min at 4 °C, followed by filtration through a 0.2-µm filter), gas exhausting, equilibrium, sample loading, rinsing, and re-equilibrium. Total viral particles (VP) were quantified using an ultraviolet spectrophotometer, with a conversion factor of 1 OD260 equal to 1.1 × 1012 VP. A batch was deemed suitable for qualitative analysis if the OD260/OD280 ratio was between 1.2 and 1.3. To validate the activity of the purified rAd5-BNoV + BNeV_VP1, HEK-293 cells were infected with the recombinant virus. RT-PCR was performed to evaluate the effectiveness of the chromatography purification. The tissue culture infectious dose of 50% (TCID50) of the purified rAd5-BNoV + BNeV_VP1 was calculated using the Reed-Muench method. To generate one-step growth curves for the recombinant adenoviruses, viral samples were collected at 12-, 24-, 36-, 48-, 60-, and 72-hours post-inoculation, and the TCID50 of each sample was measured following three freeze-thaw cycles. Immunization in mice and calves All mice and bovine trials followed the guidelines of the Sichuan Laboratory Animal Welfare and Ethics of the Sichuan Administration Committee of Laboratory Animals (China) and were approved by the Research Ethics Committee of Southwest Minzu University, China (reference number SMU-202401073). Mice and claves were housed under specific pathogen-free conditions with daily health monitoring. Fifty-four female BALB/c mice (SPF, 6–8 weeks) were housed under specific pathogen-free conditions with daily health monitoring and were randomly divided into nine groups of six mice each and vaccinated either by intramuscular (I.M.) injection or oral delivery with 2 × 105 TCID50 or 2 × 106 TCID50 of Ad5-empty (a null Ad5 vector control), rAd5-BNoV_VP1, rAd5-BNeV_VP1, or rAd5-BNoV + BNeV_VP1 (Table 1). All immunized mice received a single booster dose two weeks later. Blood samples were collected weekly from the orbital sinus to assess the magnitude and sustainability of the antibody response. Serum samples were stored at − 20 °C for detecting serum IgG antibodies and blocking antibodies. At the end of the experiment, all experimental mice were sacrificed by exsanguination after anesthesia. Table 1Types and dosages of vaccines for immunized miceGroupsTypes of vaccinesRoute of immunityDose of immunityNumberArAd5-BNoV + BNeV_VP1 (high dose)I.M.200 µL(1 × 106 TCID50 mL− 1)6BrAd5-BNoV + BNeV_VP1 (low dose)I.M.200 µL(1 × 105 TCID50 mL− 1)6CrAd5-BNoV + BNeV_VP1 (high dose)Oral200 µL(1 × 106 TCID50 mL− 1)6DrAd5-BNoV + BNeV_VP1 (low dose)Oral200 µL(1 × 105 TCID50 mL− 1)6ErAd5-BNeV_VP1 (high dose)I.M.200 µL(1 × 106 TCID50 mL− 1)6FrAd5-BNeV_VP1 (low dose)I.M.200 µL(1 × 105 TCID50 mL− 1)6GrAd5-BNoV_VP1 (high dose)I.M.200 µL(1 × 106 TCID50 mL− 1)6HrAd5-BNoV_VP1 (low dose)I.M.200 µL(1 × 105 TCID50 mL− 1)6IAd5-emptyI.M.200 µL(1 × 106 TCID50 mL− 1)6 Types and dosages of vaccines for immunized mice Six commercially raised Holstein male calves, were randomly divided into two groups, with three calves in each group (Table 2). After nasal swabs were collected from the calves, BNoV and BNeV were detected by real-time RT-PCR. The results showed that all tests were negative of BNoV and BNeV. Before immunization, we obtained serum from calves to detected IgG antibodies and blocking antibodies against both BNoV and BNeV. Only seronegative calves were selected for the immunization experiments, all of calves had received colostrum. The rAd5-BNoV + BNeV_VP1 was administered via IM injection for immunization, with a total volume of 2 mL (1 × 107 TCID50 mL− 1). The control calves were intramuscularly injected with PBS for 2 mL. All calves will receive a booster immunization at the same dose three weeks after the initial immunization. Blood samples were collected from the jugular vein of calves on days 0, 21, 35, and 49 of immunization, and serum was stored at −20 °C for detecting serum IgG antibodies and blocking antibodies. Table 2Types and dosages of vaccines for immunized calvesGroupsTypes of vaccinesRoute of immunityDose of immunityThe numberArAd5-BNoV + BNeV_VP1I.M.2 mL(1 × 107 TCID50 mL− 1)3BPBSI.M.2 mL3 Types and dosages of vaccines for immunized calves Indirect ELISA An indirect ELISA was performed in immunized mice and calves to measure serum IgG antibody titers against BNoV-VP1 or BNeV-VP1. Briefly, 96-well microplates (NEST, China) were coated with BNoV-VP1 or BNeV-VP1 proteins (0.5 µg/mL) overnight at 4 °C, followed by blocking with 5% skim milk for 2 h. Serial dilutions of serum samples were added to the microplates for binding. The microplates were then incubated with an HRP-conjugated goat anti-mouse or rabbit anti-bovine IgG antibodies (Bioss, China) with a 1:5,000 dilution. The microplates were developed using tetramethylbenzidine (TMB) substrate (NCM Biotech company, China). The endpoint titer for each serum sample was defined as the highest reciprocal serum dilution that resulted in an absorbance ≥ 2.1-fold the value of the negative control serum, indicating the presence of VP1-specific IgG antibodies. BT50 assays Due to the lack of an effective in vitro isolation and culture system for BNoV and BNeV, a histo-blood group antigen (HBGA) blocking assay was used as a surrogate to measure the neutralizing antibody response. Porcine gastric mucin-type III (PGM III), which contains type A, H, and Lewis HBGAs, can bind to the calicivirus’s VP1 protein [23]. We coated 96-well microplates (NEST, China) with PGM III (Meilunbio, China) (20 µg/mL) overnight at 4 °C and then blocked with 5% skim milk for two hours. Serum samples were initially diluted 1:20 in PBST and then serially diluted two-fold in the microplates (100 µL/well) for eight dilutions. An equal volume of BNoV-VP1 or BNeV-VP1 (1 µg/mL) was added to each well containing the diluted serum samples and incubated for one hour. Each row of serum-VP1 mixtures was then transferred to the microplates pre-coated with PGM Ⅲ and incubated for another hour. Then, polyclonal mouse anti-BNeV-VP1 antisera or anti-BNoV-VP1 antisera were added and incubated for 1 h. Subsequently, an HRP-conjugated goat anti-mouse IgG H&L antibody (1:5,000, Bioss, China) was added to the microplates. The microplates were developed using TMB (NCM Biotech company, China). The blocking rate of the serum antibody was calculated as follows: Blocking rate (%) = 1 – (OD450 of serum wells/OD450 of blank wells) × 100%. Serum blocking titer (BT50) was defined as the reciprocal of the highest serum dilution that achieved a blocking rate of ≥ 50%, indicating the ability of the serum antibody to block the binding of VP1 to HBGAs receptors. Flow cytometry assays Flow cytometry was used to quantify immune cells in splenic lymphocytes. Five female BALB/c mice (SPF, 6–8 weeks) were immunized intramuscularly (I.M.) with 200 µL (2 × 106 TCID50) of rAd5-BNoV + BNeV_VP1, while another five mice received 200 µL of Ad5-empty by I.M. as a mock control. All immunized mice received a single booster dose two weeks later. Four weeks after the initial immunization, the mice were sacrificed by exsanguination after anesthesia, and their spleens were processed into single-cell suspensions and cultured in RPMI 1640 medium containing 10% fetal bovine serum. A protein transport inhibitor (2 µL/mL, Thermo, USA), along with purified BNoV-VP1 (50 µg/mL) and BNeV-VP1 (50 µg/mL), was added to stimulate the splenic lymphocytes. The lymphocyte suspensions were treated with eBioscience™ Fixation/Permeabilization Concentrate (Thermo, USA) and incubated at 4 °C for 40 min. The cells were then stained with the following antibodies at 4 °C for 30 min: rat anti-mouse CD4-APC, rat anti-mouse CD8α-PE/CY7, hamster anti-mouse CD3ε-FITC (all from SouthernBiotech), IL-4 monoclonal antibody and IFN-γ monoclonal antibody (both from eBioscience™). The percentage of positive cells was determined using a ZE5 flow cytometer (Bio-Rad, USA), and data analysis was performed using Everest software. Statistical analysis All results were expressed as means ± standard deviation. Statistical analysis was performed using two-way ANOVA analysis and t-test analysis of variance using GraphPad 8.0 software. Significance levels were indicated as follows: ns, P ≥ 0.05, *, P < 0.05, **, P < 0.01, ***, P < 0.001, and ****, P < 0.0001. Results Construction and identification of rAd5-BNoV + BNeV_VP1 To construct recombinant shuttle plasmids, we first performed codon optimization on BNoV-VP1 based on the Bo/MILQ-1/17/CH strain (MK159173.2)and BNeV-VP1 based on the Bo/LN-13/18/CH strain (MH718898.1). The guanine and cytosine (GC) content of the BNoV-VP1 optimized gene was improved from 57.5% to 65.0% for making it well-distributed, and the codon adaptation index (CAI) was enhanced from 0.49 to 0.94 (0.8–1.0 was considered to favor protein expression). The GC content of the BNeV-VP1-optimized gene was adjusted from 60.0% to 59.2%, and the CAI was improved from 0.75 to 0.85. The genes of BNoV-VP1 and BNeV-VP1 linked together to the pDC316 vector through the P2A peptide (Fig. 1-A). The rAd5-BNoV + BNeV_VP1 was successfully packaged into HEK-293 cells, forming typical adenovirus-associated cytopathic effect (CPE) on the cells (Fig. 1-B). Construction and identification of rAd5-BNoV + BNeV_VP1. A, Schematic diagram of rAd5-BNoV + BNeV_VP1. B, the left represents the cell lesion effect caused by rAd5-BNoV + BNeV_VP1 in HEK-293 cells, and the right represents normal HEK-293 cells. C, RT-PCR of rAd5-BNoV + BNeV_VP1, M means DNA marker. D, IFA analysis of BNoV-VP1 and BNeV-VP1 protein expressed by rAd5-BNoV + BNeV_VP1 infection of HEK-293 cells. E, Western blotting analysis of BNoV-VP1 and BNeV-VP1 proteins expressed by rAd5-BNoV + BNeV_VP1 infection of HEK-293 cells To confirm the correctness of the inserted sequence in the recombinant adenovirus, the RT-PCR analysis showed that the gene sequence of BNoV + BNeV with a total length of 3324 bp was stably expressed and amplified in the cells infected with rAd5-BNoV + BNeV_VP1, indicating that rAd5-BNoV + BNeV_VP1 was successfully packaged at the gene level (Fig. 1-C). IFA and western blotting were used to examine the expressions of BNoV-VP1 and BNeV-VP1. IFA results showed that the specific green fluorescence was observed in rAd5-BNoV + BNeV_VP1-infected cells but not in the mock cells (Fig. 1-D). Western blotting revealed that two bands of approximately 57 kDa, corresponding to BNoV-VP1 and BNeV-VP1, were detected in rAd5-BNoV + BNeV_VP1-infected cells but not in the mock cells (Fig. 1-E). These findings suggest that rAd5-BNoV + BNeV_VP1 constructed using the P2A self-cleaving peptide can achieve simultaneous and efficient expression of BNoV-VP1 and BNeV-VP1 proteins when it infects HEK-293 cells. rAd5-BNoV + BNeV_VP1 purified by chromatography rAd5-BNoV + BNeV_VP1 was purified using chromatography on a Diamond Layer 700 BA and a Diamond Q Mustang. The OD260/OD280 of the purification product was 1.25, indicating that the purity met the requirements. RT-PCR showed that a gene sequence of BNoV + BNeV with a total length of 3324 bp was identified after HEK-293 cells were infected with the purification product, indicating that the product viruses were active and rAd5-BNoV + BNeV_VP1 was successfully purified (Fig. 2-A). The TCID50 of rAd5-BNoV + BNeV_VP1 was 1 × 105.68/0.1 mL. According to the one-step growth curve of rAd5-BNoV + BNeV_VP1 and Ad5-empty (Fig. 2-B), their growth kinetics were the same, which increased during 24–48 h, tended to be stable after 48 h and reached the highest value at about 60 h. rAd5-BNoV + BNeV_VP1 purified by chromatography. A, the left represents the chromatographic purification diagram of rAd5-BNoV + BNeV_VP1, and the right represents the RT-PCR of the purified product. B, Growth curve of rAd5-BNoV + BNeV_VP1 and Ad5-empty in HEK-293 cells rAd5-BNoV + BNeV_VP1 induced IgG antibodies against BNoV-VP1 and BNeV-VP1 in mice To evaluate the immunogenicity of rAd5-BNoV + BNeV_VP1, we initially detected BNoV-VP1-specific and BNeV-VP1-specific IgG antibody endpoint titers in the sera of vaccinated mice (via I.M. injection and oral delivery) and control mice (Ad5-empty) (Table 1). The immune procedure of mice is shown in Fig. 3-A. Serum samples were collected from immunized mice weekly, and antigen-specific IgG was measured. IgG antibody titers against BNoV-VP1 and BNeV-VP1 produced by rAd5-BNoV + BNeV_VP1, rAd5-BNoV or rAd5-BNeV immunized mice. A, Schematic diagram of the immunization procedure. B, IgG antibody titers in serum. Data were analyzed using one-way ANOVA followed by multiple-comparison tests. (*, P < 0.05, **, P < 0.01, ***, P < 0.001, ****, P < 0.0001, ns, P ≥ 0.05) An indirect ELISA detected the BNoV-VP1 and BNeV-VP1 specific IgG antibody titers. As shown in Fig. 3-B, the BNoV-VP1-specific IgG antibody titers of the high-dose I.M. group (n = 6) and oral group (n = 6) peaked at 1:105.0 ± 0 at three weeks post-immunization, which were significantly higher than those of low-dose I.M. group (n = 6) (1:104.0 ± 0) or low-dose oral group (n = 6) (1:103.8 ± 0.17) (P ≤ 0.05). The BNeV-VP1-specific IgG antibody titers in the high-dose I.M. group (n = 6) peaked at 1:105.0 ± 0 at three weeks post-immunization, which was significantly higher than those in the low-dose I.M. group (n = 6) (1:104.2 ± 0.17), high-dose oral group (n = 6) (1:103.8 ± 0.17) or low-dose oral group (n = 6) (1:102.8 ± 0.17) (P ≤ 0.05). These findings suggest that I.M. immunization with rAd5-BNoV + BNeV_VP1 was more effective than oral immunization, and the IgG antibody responses against BNoV-VP1 and BNeV-VP1 proteins are comparable to those induced by rAd5-BNoV_VP1 or rAd5-BNeV_VP1. rAd5-BNoV + BNeV_VP1 induced BT50 in mice The HBGA-blocking assay was used as a substitute neutralization test to determine the titers of serum-blocking antibodies in immunized mice. BT50 refers to the reciprocal of the maximum dilution of serum when the blocking rate is ≥ 50%. If serum antibodies have neutralizing abilities, they could bind to proteins and prevent proteins from binding to the receptors. The BT50 titer in the high-dose I.M. group (n = 6) was 640 ± 0 at three weeks post-immunization, which was without significant difference compared to that of the high-dose oral group (n = 6) (576 ± 64) and was significantly higher than those in the low-dose I.M. group (n = 6) (288 ± 32) or low-dose oral group (n = 6) (256 ± 39) (Fig. 4-A). The BT50 titer of the high-dose I.M. group (n = 6) was 1:640 ± 0 at four weeks post-immunization, which was significantly higher than that in the low-dose I.M. group (n = 6) (144 ± 16), high-dose oral group (n = 6) (320 ± 0) or low-dose oral group (n = 6) (144 ± 16) (P < 0.0001) (Fig. 4-B). In addition, only BNeV-VP1-specific BT50 titers were detected in the serum of immunized mice (Fig. 4-C). These findings suggest that rAd5-BNoV + BNeV_VP1 induces BNeV-VP1-specific blocking antibodies, and the effect of I.M. injection immunization was better than that of oral vaccination. BT50 in mice. A, BNeV-VP1 specific blocking ratio in serum at three weeks post-immunization. B, BNeV-VP1 specific blocking ratio in serum at four weeks post-immunization. C, BNeV-VP1 specific BT50 in serum at 3- and 4-weeks post-immunization. Data was analyzed using one-way ANOVA followed by multiple-comparison tests. (*, P < 0.05, **, P < 0.01, ***, P < 0.001, ****, P < 0.0001, ns, P ≥ 0.05) rAd5-BNoV + BNeV_VP1 induced cellular immune response in mice To assess the cellular immune response to rAd5-BNoV + BNeV_VP1, flow cytometry was used to detect the percentage of CD3+CD4+, CD3+CD8+ positive T cells and the expression of IL-4 and IFN-γ in the spleen cells of mice immunized with rAd5-BNoV + BNeV_VP1 through I.M. injection (Fig. 5A). Cellular immune response in mice. A, Schematic diagram of the immunization procedure. B, Representative flow cytometric plot for measuring CD4+/CD8+ T cells and IL-4. C, Analysis for CD4+/CD8+ T cells and IL-4. Data was analyzed using one-way ANOVA followed by multiple-comparison tests. (*, P < 0.05, **, P < 0.01, ***, P < 0.001, ****, P < 0.0001, ns, P ≥ 0.05) Figure 5-B and C show that the average percentage of CD3+ T cells produced in the I.M. group (n = 5) was 28.29%, significantly higher than in the Ad5-empty group (n = 5) (20.04%) (P = 0.0023). The average percentage of CD3+CD8+ T cells in the I.M. group (n = 5) was 29.12%, higher than that in the Ad5-empty group (n = 5) (25.85%). However, the difference was not statistically significant (P = 0.2058). The average percentage of IL-4 produced in the I.M. group (n = 5) was 2.85%, which was markedly higher than that in the Ad5-empty group (n = 5) (1.30%) (P = 0.0059). IFN-γ detection data showed abnormalities. These findings suggest that rAd5-BNoV + BNeV_VP1 induces a more robust cellular immune response through I.M. injection than the Ad5-empty group. rAd5-BNoV + BNeV_VP1 induced humoral immune response in calves To further evaluate the immunogenicity of rAd5-BNoV + BNeV_VP1 in calves, we detected BNoV-VP1-specific and BNeV-VP1-specific IgG antibody titers in the sera of vaccinated calves (via I.M. injection) and control calves (PBS) (Table 2). The immune procedure of calves is shown in Fig. 6-A. Serum samples were collected from immunized calves every two weeks after the second immunization to evaluate the humoral immune response of rAd5-BNoV + BNeV_VP1 in calves. IgG antibody titers against BNoV-VP1 and BNeV-VP1 produced by rAd5-BNoV + BNeV_VP1 immunized calves. A, Schematic diagram of the immunization procedure. B, IgG antibody titers in serum. Data were analyzed using one-way ANOVA followed by multiple-comparison tests. (*, P < 0.05, **, P < 0.01, ***, P < 0.001, ****, P < 0.0001, ns, P ≥ 0.05) An indirect ELISA detected the BNoV-VP1 and BNeV-VP1 specific IgG antibody titers. As shown in Fig. 6-B, the BNoV-VP1-specific IgG antibody titers (n = 3) reached 1:102.8 ± 0 at 21 days post-immunization and peaked at 1:104.2 ± 0.10 at 35 days post-immunization, which was significantly higher than that of PBS group (n = 3) (P ≤ 0.001). The BNeV-VP1-specific IgG antibody titers (n = 3) reached 1:102.7 ± 0.10 at 21 days post-immunization and peaked at 1:104.4 ± 0.10 at 49 days post-immunization, which was also significantly higher than that in PBS group (n = 3) (P ≤ 0.001). These findings suggest that calves immunized with rAd5-BNoV-BNeV by I.M. injection could induce a certain level of IgG antibodies against BNoV-VP1 and BNeV-VP1 proteins. To evaluate the ability of calf serum to block antibodies after immunization, a BT50 test was used to do it. BT50 refers to the reciprocal of the maximum dilution of serum when the blocking rate is > 50%. As shown in Fig. 7-A, the average BT50 titer against BNeV-VP1 in rAd5-BNoV + BNeV_VP1 group (n = 3) reached 1:80 ± 0 at 21- and 35-days post-immunization, then dropped to 1:40 ± 0 at 49 days post-immunization, which were significantly higher than that in PBS group (n = 3) (P < 0.05). In addition, only BNeV-VP1-specific BT50 titers were detected in the serum of immunized calves (Fig. 7-B). These findings suggest that immunization of calves with rAd5-BNoV + BNeV_VP1 by I.M. injection can induce a certain level of blocking antibodies against BNeV-VP1 protein. BT50 produced by rAd5-BNoV + BNeV_VP1 immunized calves. A, BNeV-VP1 specific BT50 in serum at 0-, 21-, 35- and 49-days post-immunization. B, BNeV-VP1 specific blocking ratio in serum at 0-, 21-, 35- and 49-days post-immunization. Data was analyzed using one-way ANOVA followed by multiple-comparison tests. (*, P < 0.05, **, P < 0.01, ***, P < 0.001, ****, P < 0.0001, ns, P ≥ 0.05) Discussion BNoV and BNeV are significant enteric pathogens that cause anorexia, severe watery diarrhea, and intestinal damage in calves [24, 25]. Co-infections with other enteric viruses are common and can exacerbate disease severity [26]. The absence of commercial vaccines against these viruses in China underscores the need for effective prophylactic measures. Both viruses belong to the Caliciviridae family and lack efficient in vitro culture systems, making subunit vaccine development a critical research direction. In this study, we developed a bivalent vaccine candidate using the rAd5 system, co-expressing the VP1 proteins of BNoV and BNeV via a P2A peptide linker. Our work confirms the feasibility and utility of the P2A-based multigene adenovirus vector platform and provides a practical strategy for designing engineered vaccines against BNoV and BNeV. The P2A peptide is often used as an effective tool for constructing multi-gene vectors [27]. A previous study showed that the bivalent recombinant adenovirus vaccine Ad5-G-Gn, utilizing P2A peptide as linkage, can elicit a strong humoral and cellular immune response in mice and provide significant protection against rabies virus and severe fever with thrombocytopenia syndrome infections [28]. In this study, we utilized P2A peptide as a tool to construct a bivalent recombinant adenovirus rAd5-BNoV + BNeV_VP1. RT-PCR, Western blotting, and IFA showed that BNoV-VP1 and BNeV-VP1 proteins were completely cleaved with strong biological activity and their expression levels in HEK293 cells infected with rAd5-BNoV + BNeV_VP1 were comparable to those expressed in HEK293 cells infected with the monovalent recombinant adenovirus, rAd5-BNoV or rAd5-BNeV. The rAd5 vector is an established platform for veterinary vaccine development, capable of inducing robust humoral and cellular immunity via both I.M. and oral routes [29–33]. The VP1 protein, being the major structural and immunogenic protein of caliciviruses, is a logical target for vaccine design [34–36]. Our evaluation of rAd5-BNoV + BNeV_VP1 demonstrated its ability to induce high serum IgG titers in both mice and calves. I.M. immunization consistently yielded higher antibody levels than oral administration, and the immune response elicited by the bivalent vaccine was comparable to that of its monovalent counterparts. Previous studies on oral HuNoV-VP1-rAd5 vaccines, including one incorporating a dsRNA adjuvant, reported high levels of VP1-specific IgG and blocking antibodies [37]. Kim et al. also showed that rAd5-based HuNoV tablet vaccines induced antigen-specific serum IgG [21]. Our results align with these findings, supporting the use of rAd5-VP1 vaccines to elicit potent humoral immunity. Neutralizing antibodies are a crucial index for measuring vaccine immunogenicity; nevertheless, effective in vitro isolation and culture systems for BNoV and BNeV are lacking. Previous studies showed that Calicivirus-VP1 proteins contain the carbohydrates-binding sites and major neutralizing epitopes of Calicivirus [38, 39]. A previous study showed that BNeV virus-like particles (VLPs) bound to type A/H/Lewisγ HBGAs expressed in the bovine digestive tract, suggesting a wide spectrum of HBGA recognition by BNeV [40]. Furthermore, Bucardo F et al. showed that PGM III (Porcine gastric mucin III) could bind to Norovirus due to its type H/Lewis HBGAs [41]. Therefore, to determine the blocking antibody titer induced by rAd5-BNoV + BNeV_VP1, BT50 was used as an alternative viral neutralization assay in this study. The BNeV-VP1-specific BT50 titer induced by rAd5-BNoV + BNeV_VP1 was significantly higher than that in the Ad5-empty group (P < 0.05), and the BT50 in the I.M. groups were considerably higher than that in the oral groups (P < 0.05). Studies investigated the relationship between the level of HuNoV HBGAs blocking antibodies and protection in the population. Their findings suggested that a serum HBGAs blocking antibody titer of ≥ 200 for G1.1 can protect against HuNoV [42], and a titer of ≥ 500 for GII.4 can prevent diarrhea caused by HuNoV [43]. Interestingly, the BT50 reached 640 in the high-dose I.M. group and 576 in the high-dose oral group at three weeks post-vaccination, which were both >200, suggesting that the vaccine rAd5-BNoV + BNeV_VP1 produced effective BNeV-VP1-specific blocking antibodies. However, the BNoV-VP1-specific BT50 was not detected, indicating that BNoV-VP1 uses lactose as an attachment factor, whereas PGM III only contains type A, H, and Lewis HBGAs, making it unsuitable as an attachment factor for detecting BNoV-VP1-specific BT50 [44, 45]. T lymphocytes enhance the immune effect of B cells in humoral immunity and in killing target cells in cellular immunity [46]. CD3 is a surface molecular marker of T lymphocytes, and IL-4 is involved in the humoral immune response, enhancing the antigen presentation capacity of B cells [47]. In this study, we observed that the percentage of IL-4 and CD3 + positive T lymphocytes in spleen cells of mice immunized with rAd5-BNoV + BNeV_VP1 was significantly increased compared to the Ad5-empty group, indicating that rAd5-BNoV + BNeV_VP1 induce an effective cellular immune response in mice. The immune efficacy and safety evaluation of recombinant adenovirus vaccine candidates rAd5-BNoV + BNeV_VP1 in cattle are the key indicators of whether the vaccine can be commercialized. In this study, we immunized Holstein calves with rAd5-BNoV + BNeV_VP1 via I.M. route. The results showed that rAd5-BNoV + BNeV_VP1 could induce higher levels of serum IgG and two-fold BT50 production in calves compared with the control group. Interestingly, the titers of IgG and BT50 produced by calves were lower than those produced by mice, which may be related to the immunization dose of rAd5-BNoV + BNeV_VP1 or the pre-existing maternal antibodies in calves. It is important to note that the primary limitation of this calf trial is the small group size (n = 3), which may affect the statistical power and the generalizability of the findings. Future studies with larger cohorts are warranted to confirm these results. In summary, we generated a bivalent vaccine candidate targeting BNoV-VP1 and BNeV-VP1 and evaluated its immunogenicity. The results indicated that mice and calves immunized with rAd5-BNoV + BNeV_VP1 via I.M. injection and oral administration stimulated robust humoral and cellular immune responses. These findings suggest that rAd5-BNoV + BNeV_VP1 has the potential to be an effective bivalent vaccine against BNoV and BNeV. Supplementary Information Supplementary Material 1. Acknowledgments Clinical trial numbers This study was reviewed and approved by the Animal Ethics Committee of Southwest Minzu University, with the authorization number SMU-202401073. All animal procedures were performed in strict accordance with the approved protocols. The welfare of the bovine was prioritized, and they were kept in a feeding system until natural death after the evaluation. Mice were euthanized by cervical dislocation performed by well-trained and experienced personnel and all procedures were in accordance with the AVMA Guidelines for the Euthanasia of Animals (2020 edition). Abbreviations Bovine nebovirus Bovine norovirus Enzyme-linked immunosorbent assay Reverse Transcription-Polymerase Chain Reaction Authors’ contributions B.Z., C.Y and Z.J conceived of and designed the project. T.C., C.J. and X.S. performed the experiments. Q.Y. and G.D., participated in the data acquisition and analysis. T.C. and B.Z. wrote the original draft of the manuscript. B.Z. and C.Y helped with manuscript review and editing. B.Z. and Z.J supervised the project. All the authors have read and approved the final manuscript. Funding This work was funded by Plateau Livestock Disease Prevention and Control and New Drug R&D Innovation Team of Tibet Academy of Agricultural and Animal Husbandry Science (XZNKY-2025-CXGC-T20) to B.Z.; the Program Sichuan Veterinary Medicine and Drug Innovation Group of China Agricultural Research System under Grant [SCCXTD-2024-18] to B.Z.; and Fundamental Research Funds for the Central Universities, Southwest Minzu University under Grant [ZYN2025009] to B.Z; Bamboo Diseases and Pest Control and Resources Development Key Laboratory of Sichuan Province Open Project ZLKF202507 to C.Y. Data availability The datasets used during the study are included in this article, and materials are available from the corresponding author upon request. The sequences utilized in this study have been deposited in GenBank under accession numbers MK159173.2 and MH718898.1. Declarations Ethics approval and consent to participate All animal trials followed the guidelines of the Sichuan Laboratory Animal Welfare and Ethics of the Sichuan Administration Committee of Laboratory Animals (China) and were approved by the Research Ethics Committee of Southwest Minzu University, China. All experimental procedures were strictly conducted in accordance with the regulations set forth by the Administration of Affairs Concerning Experimental Animals, as approved by the State Council of the People’s Republic of China. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Taoyun Chen and Jun Chu contributed equally to this work. Contributor Information Jiangyong Zeng, Email: zengjiangyong@126.com. Changqing Yu, Email: ycq_1926@126.com. Bin Zhang, Email: binovy@sina.com. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement The datasets used during the study are included in this article, and materials are available from the corresponding author upon request. The sequences utilized in this study have been deposited in GenBank under accession numbers MK159173.2 and MH718898.1.